Skip to main content
SpringerLink
Log in

Piracetam

  • Chapter
Book cover Neuro-Psychopharmaka

Zusammenfassung

Die pharmakologischen Wirkungen von Piracetam wurden im Tierexperiment ausgiebig untersucht. Verhaltensstudien bei gesunden jungen und alten Tieren (Giurgea 1976, Bryant et al. 1973, Wolthuis 1971, Buresova und Bures 1976), bei Tieren mit Hirnschädigungen durch Hypoxie (Giurgea et al. 1971, Sara und Lefevre 1972, Kruse und Kohler 1978, Bartus et al. 1981), nach Elektroschockbehandlung (Sara und David-Remacle 1974, Hoffmann und Rostock 1983a) und nach Intoxikation mit Scopolamin (Schindler et al. 1984), mit Cycloheximid (Krejci et al 1982) und Alkohol (Hoffmann und Rostock 1983b) zeigten unter Piracetam einen günstigen Effekt auf die Lernfähigkeit und Gedächtnisleistungen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aantaa E, Meurman OH (1975) The effect of piracetam (Nootropil UCB-6215) upon the late symptoms of patients with head injuries. J Int Med Res 3: 352–355

    Google Scholar 

  • Abbuzzahab FS, Merwin GE, Zimmermann RL, Schumann MC (1977) A double blind investigation of piracetam (nootropil) vs. placebo in geriatric memory. Pharmacopsychiatry 10: 49–56

    Google Scholar 

  • Baltes EL, Gobert JG (1977) Modeles pharmacocinétiques chez le rat, le chien et l’homme (administration orale). UCB-Publ Symp Europ Pharmacocinétique, Bruxelles, pp 99–105

    Google Scholar 

  • Bartus RT, Dean, III RL, Sherman KA, Friedmann E, Beer B (1981) Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. Neurobiol Aging 2: 105–111

    PubMed  CAS  Google Scholar 

  • Behring B, Mueller We (1985) The interaction of piracetam with several neurotransmitter receptors in the central nervous system. The relative specifity for H-glutamate sites. Arzneimittelforschung / Drug Res 35: 1350–1352

    Google Scholar 

  • Benesova O (1985) Interaction of nootropic drugs pyritinol and piracetam with the dopaminergic system. Activ Nerv [Suppl 27] 4: 284–285

    Google Scholar 

  • Bente D, Glatthaar G, Ulrich G, Lewinsky M (1978) Piracetam und Vigilanz. Elektroencephalographische und klinische Ergebnisse einer Langzeitmedikation bei gerontopsychiatrischen Patienten. Arzneimittelforschung/Drug Res 28 9–16

    Google Scholar 

  • Benzi G, Pastoris O, Villa RR, Giuffrida AM (1985) Influence of aging and exogenous substances on cerebral energy metabolism in posthypoglycemic recovery. Biochem Pharmacol 34: 1477–1483

    PubMed  CAS  Google Scholar 

  • Binder S, Doddabela P (1976) Die Wirkung von Piracetam auf das geistige Leistungsverhalten chronischer Alkoholiker. Med Klin 71: 711–716

    PubMed  CAS  Google Scholar 

  • Bjürwill BB (1985) Behandlung des hirnorganischen Psychosyndroms bei Alterspatienten mit Piracetam. Stockholm, Blackebergs Hospital. UCB-Chemie, Köln

    Google Scholar 

  • Bonifaci JF, Ferran C, Laborit H (1982) Action du piracetam sur certaines étappes du métabolisme du cerveau de rat. Agressologie 23: 127–129

    Google Scholar 

  • Bourrin JC, Chopard JL, Lassauge F, Boillot A, Rousseiat JP (1982) Lance-Adams-Syndrom. Bericht eines Falles mit positiver Entwicklung unter der Behandlung. Fait clinique, Lyon Medical 247, pp 39–43

    Google Scholar 

  • Bryant RC, Petty F, Byrne WL (1973) Effects of piracetam (SKF 38462) on acquisition, retention and acitivity in the goldfish. Psychopharmacologia (Berlin) 29: 121–130

    PubMed  CAS  Google Scholar 

  • Buresova O, Bures J (1976) Piracetam-induced facilitation of interhemispheric transfer of visual information in rats. Psychopharmacologia (Berlin) 46: 93–102

    PubMed  CAS  Google Scholar 

  • Burnotte RE, Gobert JG, Temmermann JJ (1973) Piracetam (2-pyrrolidinone acetamide) induced modifications of the brain polyribosome pattern in ageing rats. Biochem Pharmacol 22: 811–814

    PubMed  CAS  Google Scholar 

  • Calliauw L, Marchau M (1975) Clinical trial of piracetam in disorders of consciousness due to head injury. Acta Anesth Belg 2: 51–60

    Google Scholar 

  • Chase C, Tallal P (1978) Piracetam and dyslexia. A thirty-six week double-blind clinical trial. Child Health Dev 5: 140–147

    Google Scholar 

  • Chouinard G, Annable L, Ross-Chouinard A, Olivier M, Fontmne (1981) Piracetam in elderly psychiatric patients. Psychopharmacol Bull 17: 129

    PubMed  CAS  Google Scholar 

  • Connors CK, Reader M, Reiss A, Caldwell J, Caldwell L, Adesman A, Mayer L (1987) The effects of piracetam upon visual event-related potentials in dyslexic children. Psychophysiology 24: 513–521

    Google Scholar 

  • Cornely M, Henkel E, Trapp H (1978) Zur Pharmakokinetik von Piracetam während der Geburt. Fortschr Med 96: 1881–1885

    PubMed  CAS  Google Scholar 

  • Cremieux C, Serratrice G (1979) Myoclonies d’intention et d’action post-anoxique. Arnelioration par le piracetarn. Nouvelle Presse Medicale 8: 3357–3358

    PubMed  CAS  Google Scholar 

  • DE Araujo JT, Nero GS (1977) Piracetarn and acetamide in sickle-cell disease. Lancet 411–413

    Google Scholar 

  • Delawaide PR, Ylieff M, Gyselinck-Mambourg AM et al. (1975) Effecte du piracetarn sur la dernence senile. Medicine et hygiente 33: 1150–1152

    Google Scholar 

  • De Melo Gos (1976) Piracetarn in sickle-cell anaemia. Lancet i: 1139–1140

    Google Scholar 

  • Dencker SJ, Wilhelmson G, Carlsson E, Bereen FJ (1978) Piracetam and chlorrnethiazole in acute alcohol withdrawal: a controlled clinical trial. Int Med Res 6: 395–400

    CAS  Google Scholar 

  • Depresseux JC, Salmon E (1986) Evaluation of the effect of piracetam on CBF and CMRO2 in acute stroke patients, using PET and 15-oxygen. J Libbey Eurotext I: 579

    Google Scholar 

  • Dimond SJ, Brouwers EYM (1976) Increase in the power of human memory in normal man through the use of drugs. Psychopharmacology 49: 307–309

    PubMed  CAS  Google Scholar 

  • Di Ianni M, Wilsher CR, Blank MS, Connors CK, Chase CH, Funkenstein HH, Helfgott E, Holmes JM, Lougee L, Maletta G J, Milewski J, Pirozzolo FJ, Rudel RG, Tallal P (1985) The effects of piracetam in children with dyslexia. Clin Psychopharmacol 5: 272–278

    Google Scholar 

  • Dimov S, Nikolov R, Nikolova M, Moyanova S (1983) Effect of piracetam in some models of general and local depressions of the cortical bioelectrical activity in cats. Arch Int Pharmacodyn 262: 13–23

    PubMed  CAS  Google Scholar 

  • Dorn M (1978) Piracetam bei vorzeitiger biologischer Alterung. Doppelblind-Prüfung nach medikamentöser Vorselektion. Fortschr Med 96: 1525–1530

    PubMed  CAS  Google Scholar 

  • Eckmann F (1976) Klinische Untersuchungen mit Piracetam. Münch Med Wochenschr 118: 957–958

    CAS  Google Scholar 

  • Fleischmann UM (1990) Wirkeffekte nootroper Substanzen bei Alterspatienten — Eine Sekundaranalyse am Beispiel von Piracetam. Z Geront Psychiatr 4: 285–304

    Google Scholar 

  • Giurgea C (1976) Piracetam: nootropic pharmacology of neurointegrative activity. Curr Dev psychopharmacol 3: 223–273

    Google Scholar 

  • Giurgea C, Noel PR (1967) UCB 6215 (Piracetam) — Oral toxicity studies in pedigree dogs. Huntington Research Centre. Unveröffentl. Bericht UCB S.A., Bruxelles

    Google Scholar 

  • Giurgea C, Moyersoons F (1970) Differential pharmacological reactivity of three types of cortical evoked potentials. Arch Int Pharmacodyn Ther 188: 401–404

    PubMed  CAS  Google Scholar 

  • Giurgea C, Quinaux M (1978) UCB 6215 (Piracetam) — Rabbit teratology. Unveröffentl. Bericht UCB S.A., Bruxelles

    Google Scholar 

  • Giurgea C, Mouravieff-Lesuisse F, Leemans R (1970) Correlation électro-pharmacologiques au cours de l’anoxie oxyprive chez le lapin en respiration libre ou artificielle. Rev Neurol (Paris) 122: 484–486

    CAS  Google Scholar 

  • Giurgea C, Lefevre D, Lescrenier C, David-Remacle M (1971) Pharmacological protection against hypoxia induced amnesia in rats. Psychopharmacologia (Berlin) 20: 160–168

    CAS  Google Scholar 

  • Gobert JG (1972) Genése d’un medicament: le piracetam. Metabolisation et recherche biochemique. J Pharm Belg 27: 281–304

    CAS  Google Scholar 

  • Gobert JG, Baltes EL (1977) Availability and plasma clearance of piracetam in man. Il Farmaco 32: 83

    CAS  Google Scholar 

  • Grotemeyer KH, Hofferberth B, Hirschberg M (1986) Normalisierung hyperreaktiver Thrombozyten bei Patienten mit TIA’s unter Piracetam? Nervenarzt 57: 180–183

    PubMed  CAS  Google Scholar 

  • Hakkarainen H, Hakamies L (1978) Piracetam in the treatment of post-concussional syndrome. A double blind study. Eur Neurol 17: 50–55

    PubMed  CAS  Google Scholar 

  • Heiss W-D, Ilsen HW, Wagner R, Pawlik G, Wienhard K (1983) Remote functional depressions of glucose metabolism in stroke and its alteration in activating drugs. Positron emission tomography of the brain. Springer, Berlin Heidelberg New York Tokyo, pp 162–168

    Google Scholar 

  • Heiss W-D, Hebold T, Klinkhammer P, Ziffling P, Szelies B, Pawlik G, Herholz K (1988) Effect of piracetam on cerebral glucose metabolism in Alzheimer’s disease as measured by positron emission tomography. J Cereb Blood Flow Metabol 8: 613–617

    CAS  Google Scholar 

  • Herrmann WM, Kern I (1987) Nootropica: Wirkung und Wirksamkeit. Eine Überlegung am Beispiel einer Phase III-Prüfung mit Piracetam. Nervenarzt 58: 358–364

    PubMed  CAS  Google Scholar 

  • Herrschaft H (1978) Die Wirkung von Piracetam auf die Gehirndùrchblutung des menschen. Med Klin 73: 195–202

    PubMed  CAS  Google Scholar 

  • Herrschaft H (1988) Die Wirksamkeit von Piracetam bei der akuten cerebralen Ischämie des Menschen. Klinisch kontrollierte DoppelBlindstudie Piracetam / 10% Dextran 40 versus Placebo / 10% Dextran 40. Med Klin 83: 667–677

    CAS  Google Scholar 

  • Hoffmann W, Rostock A (1983a) Wirkung von Nootropica auf die durch elektrokonvulsiven Schock ausgelöste retrograde Amnesie. Pharmazie 38: 869–871

    PubMed  CAS  Google Scholar 

  • Hoffmann W, Rostock A (1983b) Der Einfluß von Nootropika auf die durch wiederholte Alkoholgabe beeinträchtigte Lernleistung von Ratten. Zbl Pharm Pharmakother Lab 122: 186

    Google Scholar 

  • Hoyer S, Krüger G, Oesterreich K, Weinhardt F (1977) Effects of drugs on cerebral blood flow and oxidative metabolism in patients with dementia. Excerpta Med Int Cong series No. 425 — Cerebrovascular disease, Proc of the 8th Int Salzburg Conference, 23–25.9. 1976. Excerpta Medica, Amsterdam Oxford, pp 25–27

    Google Scholar 

  • Hronek J, Drahokoupl L, Fait V, Hudcova T (1979) Clinical experience with Piracetam therapy in gerontology. Annual Czechoslovak Psychopharmacological Meeting. Jesenik Spa: 121–129

    Google Scholar 

  • Itel TM, Menon GN, Bozak M, Songar A (1982) The effect of oxiracetam in patients with organic brain syndrome (A double-blind controlled study with Piracetam). Drug Dev Res 2: 447–461

    Google Scholar 

  • Karakostas D, Artemis N, Karoutas G, Logothetis J (1988) Piracetam for the treatment of myoclonus secondary to herpes simplex encephalitis: case report. Acta Ther 14: 293–300

    Google Scholar 

  • Karoutas G, Artemis N, Karakostas D, Logothetis J (1988) A randomized double-blind placebo controlled study of piracetam in patients with acute ischaemic cerebral infarcts in the carotid territory. Acta Neurochir 91: 100–105

    PubMed  Google Scholar 

  • Kartin P, Povse M, Skondia V (1979) Clinical study of piracetam in patients with subacute cerebrovascular accidents. Acta Ther 5: 235–243

    Google Scholar 

  • Krejci I, Schuh J, Valchar M, Benesova C, Sulc, Kubic V, Pavlik A (1982) The effect on pyritinol and piracetam on the development of behavioral biochemical deviations induced by short-term neonatal protein synthesis inhibition in rats. Activ Nerv (Praha) [Suppl 24]: 256–259

    Google Scholar 

  • Kretschmar JH, Kretschmar C (1976) Zur DosisWirkungs-Relation bei der Behandlung mit Piracetam. Arzneimittelforschung 26: 1158–1159

    PubMed  CAS  Google Scholar 

  • Kruse H, Kohler H (1978) Memory enhancing effects of piracetam in aged rats. Fed Proc 37: 888

    Google Scholar 

  • Macchione C, Molaschi M, Fabris F, Feruglio FS (1976) Results with Piracetam in the management of senile, psycho-organic syndromes. Acta Ther 2: 261–269

    Google Scholar 

  • Maillis A, Karayanidis F, Koutsoukos E, Angelopoulos E, Stefanis C (1988) Effect of piracetam on single central neurons. Neuropsychobiology 19: 139–145

    PubMed  CAS  Google Scholar 

  • Mezitis NH (1976) Einflüsse von Piracetam auf kortikale und subkortikale Hirngebiete der Katze. Elektrophysiologische Makro- und Mikroabteilungen. Medizinische Dissertation, Heidelberg

    Google Scholar 

  • Mindus P, Cronholm B, Levander SE, Schalling D (1976) Piracetam-induced improvement of mental performance. A controlled study on normally aging individuals. Acta Psychiatr Scand 54: 150–160

    PubMed  CAS  Google Scholar 

  • Ming A, Winterton R, Fritz VU, Esser R, Hinton SA (1990) Piracetam versus placebo in first acute, non-haemorragic carotid territory stroke. A double-blind study. Int Symp on Progress of Piracetam, Athen. Ciencia y Medicina, Madrid, pp 88–93

    Google Scholar 

  • Miler WE (1988) Veränderung zentraler Neurorezeptoren unter besonderer Berücksichtigung der m-Cholinrezeptoren, ein Aspekt des biologischen Alterns. In: Helmchen H (Hrsg) Wirkungen und Wirksamkeit von Nootropika. Springer, Berlin Heidelberg New York Tokyo, S 42–61

    Google Scholar 

  • Nickolson V, Wolthuis OL (1976) Protein metabolism in the rat cerebral cortex in vivo and in vitro as affected by the aquisition-enhancing drug piracetam. Biochem Pharmacol 25: 2241–2244

    PubMed  CAS  Google Scholar 

  • Nickolson VJ, Wolthuis OL (1976a) Differential effects of the aquisition drug pyrrolidone acetamide (piracetam) on the release of proline from visual and parietal rat cerebral cortex in vitro. Brain Res 113: 616–619

    PubMed  CAS  Google Scholar 

  • Nikolova M, Tsikalova R, Taskov M (1979) Simultaneous investigations of the cerebral circulation and cortical bioelectrical activity in dogs under the influence of piracetam. Meth Find Exp Clin Pharmacol 1: 97–104

    CAS  Google Scholar 

  • Nikolova M, Tsikalova R, Taskov M, Vlahov V (1980a) Experimental rheoencephalographic and electroencephalographic investigations on piracetam. Meth Find Exp Clin Pharmacol 2: 327–333

    CAS  Google Scholar 

  • Nikolova M, Nikolov R, Tsikalova R, Popivanov D (1980b) Piracetam effect on the visual evoked potentials in cats. Drugs Exp Clin Res 6: 33–37

    CAS  Google Scholar 

  • Nybck H, Wiesel F-A, Skett P (1979) Effects of piracetam on brain monoamine metabolism and serum prolactin levels in rat. Psychopharmacology 61: 235–238

    Google Scholar 

  • Obeso JA, Artieda J, Luquin MR, Vaanmonde J, Martinez Lage J M (1986) Antimyoklonische Wirkung von Piracetam. Clin Neuropharmacol 9: 58–64

    PubMed  CAS  Google Scholar 

  • Olpe H-R, Steinmann MW (1982) The effect of vincamine, hydergine and piracetam on the firing rate of locus coeruleus neurons. J Neural Transm 55: 101–109

    PubMed  CAS  Google Scholar 

  • Ostrovskaya R U, Hoffmann W, Molodwakin G M (1983) Untersuchungen zur antihypoxischen Wirksamkeit von Tisochromid (16–244) im Vergleich zu Piracetam. Pharmazie 38: 251–253

    PubMed  CAS  Google Scholar 

  • Ostrowski J, Keil M (1978) Autoradiographische Untersuchungen zur Verteilung von 14-C-Piracetam im Affengehirn. Arzneimittelforschung/Drug Res 28: 29–35

    CAS  Google Scholar 

  • Ostrowski J, Keil M, Schraven E (1975) Autoradiographische Untersuchungen zur Verteilung von Piracetam-14 C bei Ratte und Hund. Arzneimittelforschung/Drug Res 25: 589–596

    CAS  Google Scholar 

  • Ott E (1988) Behandlungsergebnisse mit Piracetam bei der Multi-Infarkt-Demenz. In: Helmchen H (Hrsg) Wirkungen und Wirksamkeit von Nootropika. Springer, Berlin Heidelberg New York Tokyo, S 162–168

    Google Scholar 

  • Parrisius HW (1977) Doppelblindstudie mit Piracetam in der Geriatrie. Geriatrie 7: 32–37

    Google Scholar 

  • Pede JP, Schimpfessel L, Crokaert R (1983) The action of piracetam on the oxidative phosphorylation. Drugs Exp Clin Res 9: 853–871

    Google Scholar 

  • Pellegata R (1981) Cyclic GABA-GABOB analogues. III. Synthesis and biochemical activity of new alkyl and acyl derivatives of 4-hydroxy-2-pyrrolidinone. June Farmaco (Edizione Scientifical) 36 (10): 845–855

    CAS  Google Scholar 

  • Perez GM (1981) Evaluation of the clinical efficacy of piracetam in the deterioration of the intellectual functions of a geriatric population: a double-blind study. Second International Symposium on Nootropic Drugs, Mexico. UCB-Publ, pp 53–62

    Google Scholar 

  • Peuvot J (1990) Piracetam in the treatment of myoclonus. In: Piracetam, 5 year progress in pharmacology and clinics. Int Symp, Athen 1990. Ciencia y Medicina, Madrid, pp 101–107

    Google Scholar 

  • Platt D, Hering H, Hering FJ (1974) Messungen lysosomaler Enzym-Aktivitäten sowie von Leuzin-Inkorporationsraten im Gehirn junger und alter Ratten nach Gabe von Piracetam. Arzneimittelforschung/Dmg Res 24: 1588–1590

    CAS  Google Scholar 

  • Raego LK, Allkimets LH, Zarkovsky AM (1981) Effects of Piracetam on the central dopaminergic transmission. Naunyn Schmiedebergs Arch Pharmacol 319: 17–36

    Google Scholar 

  • Reisberg B, Ferris SH, Schneck MK, Corwin J, Mir P, Friedeman E, Sherman KA, Mccarthy M, Bartus RT (1982) Piracetam in the treatment of cognitive impairment in the elderly. Drug Dev Res 2: 475–480

    Google Scholar 

  • Richardson AE, Bereen F J (1977) Effects of Piracetam on level consciousness after neurosurgery. Lancet ii: 1110–1111

    Google Scholar 

  • Sara SJ, Lefevre D (1972) Hypoxia-induced amnesia in one-trial learning and pharmacological protection by piracetam. Psychopharmacologia (Berlin) 25: 32–40

    CAS  Google Scholar 

  • Sara SJ, David-Remacle M (1974) Recovery from electroconvulsive shock-induced amnesia by exposure to the training environment: pharmacological enhancement by piracetam. Psychopharmacologia (Berlin) 36: 59–66

    CAS  Google Scholar 

  • Schenk GK, Engelmeier M-P, Lodemann E, Pach J (1982) Vigilanz, hirnorganisches Psychosyndrom und Pharmakotherapie. Aspekte der Reversibilität. In: Bente D, H. Kanowski (Hrsg) Hirnorganische Psychosyndrome im Alter — Konzepte und Modelle für die pharmakotherapeutische Forschung. Springer, Berlin Heidelberg New York Tokyo, S 74–113

    Google Scholar 

  • Schindler U, Rush DK, Fielding S (1984) Nootropic drugs: animal models for studying effects on cognition. Drug Dev Res 4: 567–576

    CAS  Google Scholar 

  • Schulz HU, Wittler T (1980) Age-related changes in pharmacokinetics of piracetam in man. Arch Pharmacol [Suppl]: 38–46

    Google Scholar 

  • Skondia V, Kabes J (1985) Piracetam in alcoholic psychosis. A double-blind cross-over, placebo controlled study. Int Med Res 13: 185–187

    CAS  Google Scholar 

  • Snel H, Lehman E, Velikonja M (1983) Piracetam in der Behandlung des alkoholbedingten Delirs. Münch Med Wochenschr 42: 947–949

    Google Scholar 

  • Sonnet J, Gini EK, Cornu G (1985) Essai de prévention des crisis vaso-occulsives de la drepanocytes homozygote par le piracetam. Ann Soc Belg Med Trop 65: 77–84

    PubMed  CAS  Google Scholar 

  • Stegink AJ (1972) The clinical use of piracetam, a new nootropic drug. The treatment of symptoms of senile involution. Arzneimittelforschung / Drug Res 22: 975–977

    CAS  Google Scholar 

  • Suzuki et al. (1973) UCB-Dipha Bericht 1970

    Google Scholar 

  • Ulbricht B (1976) Über die klinische Anwen dung von Piracetam bei chronischem Alkoholismus und dessen Komplikationen Prädelir und Delir. Med Welt 27: 1912–1915

    PubMed  CAS  Google Scholar 

  • Valzelli L, Bernasconi S, Sala A (1990) Piracetam activity may differ according to the age of the recipient mouse. Int Pharmacopsychiatry 15: 150–156

    Google Scholar 

  • Welbel L (1981) Piracetam v/s Pyritinol in the treatment of psychoorganic syndrome patients. Second International Symposium of Nootropic Drugs, Mexico. UCB-Publ, pp 66–70

    Google Scholar 

  • Weth G (1983) The influence of piracetam on the cyclic adenosine monophosphate (cAMP) concentration in the brain and colon of guinea pigs. Arzneimittelforschung /Drug Res 3(I)/6: 812–814

    Google Scholar 

  • Wilsher CR et al. (1987) Piracetam and dyslexia : effects on reading tests. J Clin Psychopharmacol 7: 230–237

    PubMed  CAS  Google Scholar 

  • Woelk H (1979) Effects of piracetam on the incorporation of 32 P into the phospholipids of neurons and glial cells isolated from rabbit cerbral cortex. Pharmakopsychiatry 12: 251–256

    CAS  Google Scholar 

  • Woelk H, Peiler-Ichikawa K (1978) The action of piracetam on the formation of ethanolamineplasmalogen by neuronal microsomes of the developing pig brain. Arzneimittelforschung/ Drug Res 28: 1752–1756

    CAS  Google Scholar 

  • Wolthuis OL (1971) Experiments with UCB 6215, a drug which enhances acquisition in rats: its effects compared with those of metamphetamine. Eur J Pharmacol 16: 283–297

    PubMed  CAS  Google Scholar 

  • Wouthuis OL (1971) Experiments with UCB 6215, a drug which enhances acquisition in rats: its effects compared with those of metamphetamine. Eur J Pharmacol 16: 283–297

    Google Scholar 

  • Wurtmann RJ, Magil DC, Reinstein DK (1981) Piracetam diminishes hippocampal acetylcholine levels in rats. Life Sci 28: 1091–1093

    Google Scholar 

Download references

Authors
  1. H. Herrschaft
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Universitätsklinik, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Psychiatrische Universitätsklinik, Bonn, Bundesrepublik Deutschland

    Gerd Laux

  3. Psychiatrische Universitätsklinik, Basel, Schweiz

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Wien

About this chapter

Cite this chapter

Herrschaft, H. (1992). Piracetam. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3330-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3330-9_12

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3331-6

  • Online ISBN: 978-3-7091-3330-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation